

Martin J S Dyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4805176/publications.pdf>

Version: 2024-02-01

192
papers

15,420
citations

15880

67
h-index

21239

119
g-index

194
all docs

194
docs citations

194
times ranked

17674
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic lymphocytic leukaemia therapy: is less more?. <i>Lancet Haematology</i> , 2022, 9, e169-e171.	2.2	0
2	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	2.5	22
3	Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2022, 6, e752.	1.2	1
4	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9
5	Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 133-145.	1.4	12
6	Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis. <i>Leukemia</i> , 2021, 35, 2407-2411.	3.3	3
7	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
8	A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 309-317.e3.	0.2	17
9	Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. <i>Haematologica</i> , 2021, 106, 2774-2778.	1.7	12
10	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2108-2113.	3.3	13
11	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , 2020, 34, 1458-1461.	3.3	15
12	Phase 1b Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2020, 26, 2810-2818.	3.2	46
13	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, 2150-2163.	1.7	30
14	Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 525-529.	2.5	8
15	Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2765-2775.	0.6	63
16	Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2019, 104, e68-e71.	1.7	97
17	Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. <i>Haematologica</i> , 2019, 104, 1016-1025.	1.7	14
18	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40

#	ARTICLE	IF	CITATIONS
19	DNA methylation profiling of hepatosplenic T-cell lymphoma. <i>Haematologica</i> , 2019, 104, e104-e107.	1.7	11
20	<sc>CUDC</sc>â€907 blocks multiple proâ€survival signals and abrogates microenvironment protection in <sc>CLL</sc>. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 340-348.	1.6	22
21	Differential activation of proâ€survival pathways in response to <sc>CD</sc>40<sc>LG</sc>/<sc>IL</sc>4 stimulation in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2019, 184, 867-869.	1.2	3
22	A multiâ€centre phase I trial of the <sc>PARP</sc> inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, Tâ€prolymphocytic leukaemia or mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 429-433.	1.2	23
23	Enforced expression of MIR142, a target of chromosome translocation in human B-cell tumors, results in B-cell depletion. <i>International Journal of Hematology</i> , 2018, 107, 345-354.	0.7	4
24	Paradoxical activation of alternative proâ€survival pathways determines resistance to <i><sc>MEK</sc></i> inhibitors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 921-924.	1.2	6
25	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1530-1542.	5.1	91
26	Responses to the Selective Brutonâ€™s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. <i>Cancers</i> , 2018, 10, 127.	1.7	26
27	SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2018, 9, 22872-22885.	0.8	11
28	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	5.8	75
29	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. <i>Haematologica</i> , 2017, 102, 765-772.	1.7	21
30	Targeting antiâ€apoptotic <sc>BCL</sc>2 family proteins in haematological malignancies â€ from pathogenesis to treatment. <i>British Journal of Haematology</i> , 2017, 178, 364-379.	1.2	74
31	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. <i>Haematologica</i> , 2017, 102, e360-e363.	1.7	27
32	Long-term follow-up of patients with CLL treated with the selective Brutonâ€™s tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , 2017, 129, 2808-2810.	0.6	48
33	CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. <i>Cancer Research</i> , 2017, 77, 1097-1107.	0.4	59
34	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	2.0	79
35	Genes encoding members of the <sc>JAK</sc>â€<sc>STAT</sc> pathway or epigenetic regulators are recurrently mutated in Tâ€cell prolymphocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 173, 265-273.	1.2	64
36	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. <i>Nature Communications</i> , 2016, 7, 11889.	5.8	42

#	ARTICLE	IF	CITATIONS
37	Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2319-2326.	0.6	90
38	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , 2016, 127, 411-419.	0.6	231
39	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	0.6	100
40	Posttranscriptional Upregulation of p53 by Reactive Oxygen Species in Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2016, 76, 6311-6319.	0.4	5
41	Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia. <i>British Journal of Haematology</i> , 2016, 175, 641-651.	1.2	26
42	Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 668-680.	1.5	23
43	Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2015, 170, 40-49.	1.2	14
44	Recurrent CDKN1B (p27) mutations in hairy cell leukemia. <i>Blood</i> , 2015, 126, 1005-1008.	0.6	88
45	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015, 100, e311-4.	1.7	15
46	Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331). <i>Blood</i> , 2015, 126, 494-494.	0.6	23
47	Efficacy of Vemurafenib in Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 286-288.	13.9	56
48	A Double Hit CD10-Negative B-Cell Lymphoma with t(3;8)(q27;q24) Leading to Juxtaposition of the BCL6 and MYC Loci Associated with Good Clinical Outcome. <i>Case Reports in Hematology</i> , 2014, 2014, 1-5.	0.3	7
49	Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma - a phase II trial. <i>British Journal of Haematology</i> , 2014, 165, 575-578.	1.2	34
50	Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18078-18083.	3.3	74
51	Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 309-316.	1.5	79
52	Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 12-22.	1.2	15
53	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	9.4	166
54	Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lincatutumumab in adult patients with advanced non-Hodgkin or H ₂ O ₂ lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 258-265.	1.2	65

#	ARTICLE	IF	CITATIONS
55	MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. <i>Haematologica</i> , 2014, 99, 1285-1291.	1.7	2
56	Ask the Experts: Precision medicines: a new era for the treatment of B-cell malignancies. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 113-116.	0.7	0
57	<scp>ABT</scp>â€199 selectively inhibits <scp>BCL</scp>2 but not <scp>BCL</scp>2<scp>L</scp>1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. <i>British Journal of Haematology</i> , 2013, 163, 139-142.	1.2	93
58	Precision medicines for Bâ€cell leukaemias and lymphomas; progress and potential pitfalls. <i>British Journal of Haematology</i> , 2013, 160, 725-733.	1.2	11
59	BCL7A protein expression in normal and malignant lymphoid tissues. <i>British Journal of Haematology</i> , 2013, 160, 106-109.	1.2	9
60	The Detection of Chromosomal Translocations Involving the Immunoglobulin Loci in B-Cell Malignancies. <i>Methods in Molecular Biology</i> , 2013, 971, 123-133.	0.4	3
61	Enhancement of <scp>CD</scp>154/<scp>IL</scp>4 proliferation by the <scp>T</scp> follicular helper (<scp>T</scp>fh) cytokine, <scp>IL</scp>21 and increased numbers of circulating cells resembling <scp>T</scp>fh cells in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 162, 360-370.	1.2	52
62	Prdm6 Is Essential for Cardiovascular Development In Vivo. <i>PLoS ONE</i> , 2013, 8, e81833.	1.1	15
63	Biallelic <i>ATM</i> Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 4524-4532.	0.8	109
64	ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. <i>Haematologica</i> , 2012, 97, 142-146.	1.7	32
65	Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 199-207.	1.1	7
66	t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth. <i>Blood</i> , 2012, 120, 3949-3957.	0.6	48
67	Highâ€throughput sequencing analysis of the chromosome 7q32 deletion reveals <scp>IRF</scp>5 as a potential tumour suppressor in splenic marginalâ€zone lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 712-726.	1.2	45
68	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 843-846.	0.6	76
69	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 446-467.	1.2	58
70	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 499-507.	1.2	44
71	The <i>CBFA2T3/ACSF3</i> locus is recurrently involved in <i>IGH</i> chromosomal translocation t(14;16)(q32;q24) in pediatric Bâ€cell lymphoma with germinal center phenotype. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 338-343.	1.5	18
72	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2011, 408, 344-349.	1.0	16

#	ARTICLE	IF	CITATIONS
73	BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. <i>Blood</i> , 2011, 117, 7145-7154.	0.6	161
74	TP53 codon 72 polymorphism in patients with chronic lymphocytic leukaemia: identification of a subgroup with mutated IGHV genes and poor clinical outcome. <i>British Journal of Haematology</i> , 2011, 153, 533-535.	1.2	10
75	Alemtuzumab-resistant B-cell hairy syndrome responding to zanolimumab*. <i>British Journal of Haematology</i> , 2011, 154, 419-421.	1.2	11
76	Primary lymphoma-like lesions of the uterine cervix; sheep in wolves'™ clothing. <i>British Journal of Haematology</i> , 2011, 153, 791-794.	1.2	12
77	Bilateral subdural hygromas following intrathecal methotrexate. <i>British Journal of Haematology</i> , 2011, 155, 536-536.	1.2	4
78	pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1. <i>Trends in Cell Biology</i> , 2011, 21, 20-28.	3.6	89
79	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011, 35, 750-756.	0.4	60
80	Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation. <i>Leukemia Research</i> , 2011, 35, e55-e57.	0.4	1
81	Immunoglobulin heavy chain locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia: rare clinical curios or potent genetic drivers?. <i>Blood</i> , 2010, 115, 1490-1499.	0.6	56
82	Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. <i>Blood</i> , 2010, 116, 1317-1320.	0.6	44
83	Proteomic analysis of B-cell malignancies. <i>Journal of Proteomics</i> , 2010, 73, 1804-1822.	1.2	17
84	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 132-136.	9.4	223
85	HVCN1 modulates BCR signal strength via regulation of BCR-dependent generation of reactive oxygen species. <i>Nature Immunology</i> , 2010, 11, 265-272.	7.0	196
86	Laparoscopic splenectomy: a personal series of 140 consecutive cases. <i>Annals of the Royal College of Surgeons of England</i> , 2010, 92, 398-402.	0.3	21
87	Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1749-1755.	0.8	541
88	The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. <i>Blood</i> , 2010, 116, 4578-4587.	0.6	271
89	Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. <i>Human Molecular Genetics</i> , 2010, 19, 1840-1845.	1.4	24
90	Diminished Sensitivity of Chronic Lymphocytic Leukemia Cells to ABT-737 and ABT-263 Due to Albumin Binding in Blood. <i>Clinical Cancer Research</i> , 2010, 16, 4217-4225.	3.2	45

#	ARTICLE	IF	CITATIONS
91	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2010, 95, 1510-1518.	1.7	73
92	Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. <i>Blood</i> , 2010, 115, 5393-5397.	0.6	212
93	Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. <i>Blood</i> , 2010, 115, 4393-4402.	0.6	782
94	Identification of Thr29 as a Critical Phosphorylation Site That Activates the Human Proton Channel Hvcn1 in Leukocytes. <i>Journal of Biological Chemistry</i> , 2010, 285, 5117-5121.	1.6	59
95	A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms. <i>PLoS ONE</i> , 2009, 4, e6986.	1.1	115
96	Voltage-gated proton channels maintain pH in human neutrophils during phagocytosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18022-18027.	3.3	161
97	Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 3088-3097.	1.9	31
98	Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results. <i>Journal of Clinical Oncology</i> , 2009, 27, 3346-3353.	0.8	154
99	Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma. <i>Molecular and Cellular Proteomics</i> , 2009, 8, 1501-1515.	2.5	78
100	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2009, 144, 317-331.	1.2	28
101	Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing. <i>British Journal of Haematology</i> , 2009, 146, 384-395.	1.2	20
102	Caspase cleavage of Itch in chronic lymphocytic leukemia cells. <i>Biochemical and Biophysical Research Communications</i> , 2009, 379, 659-664.	1.0	20
103	Identification of Phosphorylation Sites that Activate Voltage Gated Proton Channels in Leukocytes. <i>Biophysical Journal</i> , 2009, 96, 170a-171a.	0.2	1
104	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , 2009, 114, 2273-2279.	0.6	523
105	p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 6498-6499.	0.6	11
106	Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 2561-2562.	0.6	9
107	Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. <i>Blood</i> , 2009, 114, 4843-4846.	0.6	27
108	Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009, 113, 4403-4413.	0.6	294

#	ARTICLE	IF	CITATIONS
109	Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2009, 114, 2688-2698.	0.6	445
110	Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2009, 94, 1020-1023.	1.7	28
111	Receptor-selective TRAIL Mutants Target Lymphoid Tumor cells for Apoptosis via TRAIL-R1: Implications for Therapy. <i>Toxicology</i> , 2008, 253, 6-7.	2.0	1
112	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2008, 40, 1204-1210.	9.4	329
113	t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). <i>Blood</i> , 2008, 111, 387-391.	0.6	59
114	BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 $\alpha^{\prime}938A$ promoter single nucleotide polymorphism. <i>Blood</i> , 2008, 111, 874-877.	0.6	42
115	DAT \pm AHA = bad CLL. <i>Blood</i> , 2008, 111, 1757-1757.	0.6	0
116	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008, 111, 5691-5693.	0.6	30
117	The Voltage-Gated Proton Channel HVCN1 Co-Localizes with B Cell Receptor and Is Involved in Class Switch Recombination in Vivo. <i>Blood</i> , 2008, 112, 707-707.	0.6	4
118	Mutation Status of the Residual ATM Allele Is an Important Determinant of the Cellular Response to Chemotherapy and Survival in Patients With Chronic Lymphocytic Leukemia Containing an 11q Deletion. <i>Journal of Clinical Oncology</i> , 2007, 25, 5448-5457.	0.8	224
119	Barriers to Effective TRAIL-Targeted Therapy of Malignancy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4505-4506.	0.8	89
120	Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). <i>Blood</i> , 2007, 109, 3451-3461.	0.6	188
121	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. <i>Blood</i> , 2007, 110, 3326-3333.	0.6	79
122	David Galton – the thesis years. <i>Leukemia and Lymphoma</i> , 2007, 48, 2290-2291.	0.6	0
123	Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. <i>Blood</i> , 2007, 109, 271-280.	0.6	227
124	Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 406-415.	1.5	77
125	Trisomy 19 is associated with trisomy 12 and mutated IGHV genes in B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007, 138, 217-220.	1.2	40
126	TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. <i>British Journal of Haematology</i> , 2007, 139, 568-577.	1.2	64

#	ARTICLE	IF	CITATIONS
127	Proteomic Analysis of Cell Surface Membrane Proteins in Leukemic Cells. <i>Methods in Molecular Biology</i> , 2007, 370, 135-146.	0.4	3
128	Functional studies of BCL11A: characterization of the conserved BCL11A-XL splice variant and its interaction with BCL6 in nuclear paraspeckles of germinal center B cells. <i>Molecular Cancer</i> , 2006, 5, 18.	7.9	74
129	Transcriptional silencing of Polo-like kinase 2(SNK/PLK2)is a frequent event in B-cell malignancies. <i>Blood</i> , 2006, 107, 250-256.	0.6	112
130	Chromosomal Translocations Fusing the <i>BCL6</i> Gene to Different Partner Loci Are Recurrent in Primary Central Nervous System Lymphoma and May Be Associated With Aberrant Somatic Hypermethylation or Defective Class Switch Recombination. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 776-782.	0.9	53
131	Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2006, 132, 115-116.	1.2	20
132	Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. <i>International Journal of Cancer</i> , 2006, 118, 1941-1944.	2.3	59
133	Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13485-13490.	3.3	61
134	Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. <i>Cancer Research</i> , 2006, 66, 6785-6792.	0.4	124
135	Rituximab-Relapsing Patients with Non-Hodgkins Lymphoma Respond Even at Lower Doses of Humanized Anti-CD20 Antibody, IMMU-106 (hA20): Phase I/II Results.. <i>Blood</i> , 2006, 108, 2719-2719.	0.6	7
136	Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. <i>Blood</i> , 2005, 105, 4445-4454.	0.6	180
137	No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Selzary syndrome. <i>Blood</i> , 2005, 105, 4148-4149.	0.6	41
138	Report: workshop on mediastinal grey zone lymphoma. <i>European Journal of Haematology</i> , 2005, 75, 45-52.	1.1	19
139	Cloning of Immunoglobulin Chromosomal Translocations by Long-Distance Inverse Polymerase Chain Reaction. , 2005, 115, 217-230.		4
140	TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies. <i>Cancer Research</i> , 2005, 65, 11265-11270.	0.4	152
141	A High-Density SNP Genomewide Linkage Scan for Chronic Lymphocytic Leukemia- Susceptibility Loci. <i>American Journal of Human Genetics</i> , 2005, 77, 420-429.	2.6	65
142	Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. <i>Blood</i> , 2005, 106, 3214-3222.	0.6	137
143	The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics. <i>FASEB Journal</i> , 2005, 19, 1187-1189.	0.2	77
144	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. <i>Human Molecular Genetics</i> , 2004, 13, 1827-1837.	1.4	115

#	ARTICLE	IF	CITATIONS
145	Management Guidelines for Use of Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2004, 4, 220-227.	2.1	91
146	The Pathogenetic Role of Oncogenes Deregulated by Chromosomal Translocation in B-Cell Malignancies. <i>International Journal of Hematology</i> , 2003, 77, 315-320.	0.7	21
147	Interphase cytogenetic characterization of aberrations in the long arm of chromosome 1 in B-cell lymphoid malignancies. <i>Cancer Genetics and Cytogenetics</i> , 2003, 144, 83-84.	1.0	5
148	Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. <i>Oncogene</i> , 2003, 22, 2643-2654.	2.6	102
149	MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2003, 101, 4539-4546.	0.6	188
150	Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma. <i>Leukemia and Lymphoma</i> , 2003, 44, 459-464.	0.6	24
151	Bioweapons of Tumor Mass Destruction?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3011-3012.	0.8	2
152	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. <i>Blood</i> , 2003, 101, 3109-3117.	0.6	212
153	High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma. <i>Blood</i> , 2003, 101, 2547-2550.	0.6	137
154	Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2003, 101, 2756-2761.	0.6	61
155	Mature T-cell Malignancies. <i>Human Cell Culture</i> , 2002, , 321-337.	0.1	0
156	Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. <i>Blood</i> , 2002, 99, 1474-1477.	0.6	224
157	Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. <i>International Journal of Cancer</i> , 2002, 98, 470-474.	2.3	84
158	Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. <i>Oncogene</i> , 2002, 21, 6809-6818.	2.6	183
159	Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. <i>Blood</i> , 2001, 98, 3479-3482.	0.6	86
160	The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. <i>Blood</i> , 2001, 98, 3413-3420.	0.6	273
161	High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. <i>Blood</i> , 2001, 98, 1721-1726.	0.6	307
162	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. <i>Blood</i> , 2001, 98, 2837-2844.	0.6	125

#	ARTICLE	IF	CITATIONS
163	Pituitary infiltration in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 115, 718-718.	1.2	19
164	Proteolytic Cleavage of Molecules Involved in Cell Death or Survival Pathways: A Role in the Control of Apoptosis?. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2001, 11, 10.	0.4	14
165	BCL10 gene mutation in lymphoma. <i>Blood</i> , 2000, 95, 3885-3890.	0.6	109
166	CARD9 Is a Novel Caspase Recruitment Domain-containing Protein That Interacts With BCL10/CLAP and Activates NF- κ B. <i>Journal of Biological Chemistry</i> , 2000, 275, 41082-41086.	1.6	221
167	BCL10 Expression in Normal and Neoplastic Lymphoid Tissue. <i>American Journal of Pathology</i> , 2000, 157, 1147-1154.	1.9	183
168	BCL10 gene mutation in lymphoma. <i>Blood</i> , 2000, 95, 3885-3890.	0.6	7
169	Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. , 1999, 25, 222-229.		24
170	Bcl10 Is Involved in t(1;14)(p22;q32) of MALT B Cell Lymphoma and Mutated in Multiple Tumor Types. <i>Cell</i> , 1999, 96, 35-45.	13.5	656
171	In Response to Fakruddin et al. and Apostolou et al. <i>Cell</i> , 1999, 97, 686-688.	13.5	17
172	Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. <i>Leukemia Research</i> , 1998, 22, 185-191.	0.4	262
173	The BCL7 gene family: deletion of BCL7B in Williams syndrome. <i>Gene</i> , 1998, 224, 35-44.	1.0	43
174	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , 1998, 92, 2871-2878.	0.6	80
175	DNA Fiber Fluorescence In Situ Hybridization Analysis of Immunoglobulin Class Switching in B-Cell Neoplasia: Aberrant CH Gene Rearrangements in Follicle Center-Cell Lymphoma. <i>Blood</i> , 1998, 92, 2871-2878.	0.6	21
176	p53 Abnormalities in B-Cell Prolymphocytic Leukemia. <i>Blood</i> , 1997, 89, 2015-2023.	0.6	115
177	Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia. <i>Nature Genetics</i> , 1997, 17, 96-99.	9.4	257
178	Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1996, 93, 151-153.	1.2	219
179	IgD class switching: Identification of a novel recombination site in neoplastic and normal B cells. <i>European Journal of Immunology</i> , 1995, 25, 3504-3508.	1.6	51
180	Characterization of a t(10; 11) (p13-l4; q14-21) in the monoblastic cell line U937. <i>Genes Chromosomes and Cancer</i> , 1995, 13, 138-142.	1.5	8

#	ARTICLE	IF	CITATIONS
181	Immunoblastic Transformation of a Sezary Syndrome in a Black Caribbean Patient Without Evidence of HTLV-I. <i>Leukemia and Lymphoma</i> , 1995, 18, 521-527.	0.6	4
182	Acute myelomonocytic leukemia with t(10;11)(p13;q23): Heterogeneity of breakpoints at 11q23 and association with recombinase activation. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 136-139.	1.5	12
183	Persistent polyclonal B-cell lymphocytosis. <i>Leukemia Research</i> , 1994, 18, 791-795.	0.4	29
184	Lack of MDM2 amplification in human leukaemia. <i>British Journal of Haematology</i> , 1994, 86, 407-409.	1.2	21
185	Chimeric antibodies for the treatment of hematologic malignancy. <i>Cancer Treatment and Research</i> , 1993, 68, 161-180.	0.2	1
186	T-Cell Receptor and Immunoglobulin Gene Rearrangements in Acute Myeloid and Undifferentiated Leukemias of Adults: Correlation with Weak Surface Expression of CD45 and CDw52 Antigens. <i>Leukemia and Lymphoma</i> , 1991, 3, 257-265.	0.6	5
187	The CAMPATH-1 antigen (CDw52). <i>Tissue Antigens</i> , 1990, 35, 118-127.	1.0	328
188	Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. <i>Leukemia and Lymphoma</i> , 1990, 2, 179-193.	0.6	67
189	The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. <i>European Journal of Immunology</i> , 1989, 19, 381-388.	1.6	42
190	Monoclonal Antibodies for Immunosuppression. <i>Chemical Immunology and Allergy</i> , 1988, 45, 16-30.	1.7	4
191	Monoclonal Antibodies for Immunosuppression. <i>Chemical Immunology and Allergy</i> , 1988, 45, 16-30.	1.7	1
192	Proteomic Analysis of Cell Surface Membrane Proteins in Leukemic Cells. , 0, , 135-146.		0